Will the BEAUTIFUL Study results change our views on heart rate control?
Abstract
The article describes the results of a randomized, double-blind, placebo-controlled, parallel-group BEAUTIFUL trial. The position of an If inhibitor ivabradine in the current algorithm of antianginal therapy is analyzed
About the Author
Yu. M. Lopatin
Volgograd State Medical University, Volgograd Region Cardiology Center. Volgograd
Russian Federation
Russian Federation
References
1. Wilhelmsen I, Berglung G, Elmfeldt D, et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J 1986; 7: 279-88.
2. Palatini P, Casiglia E, Pauletto P. Relation between physical training and ambulatory blood pressure in stage I hypertensive subjects: results of the HARVEST trial. Circulation 1994; 90: 2870-2.
3. Diaz A, Bourassa GM, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.
4. Hjalmarson A, Gilpin E, Kjekshus J, et al. Influence of heart rate onmortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-53.
5. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999; 1(Suppl H): H64-9.
6. Poldermans D, Bax JJ, Schouten O, et al. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? JACC 2006; 48: 964-9.
7. Beere PA, Glagov S, Zarins CR. Retarding effects of lowering heart rate on coronary atherosclerosis. Science 1984; 226: 180-2.
8. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate associated with coronary plaque distruption. Circulation 2001; 104: 1477-82.
9. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.
10. Диагностикаи лечение стабильной стенокардии. Российские рекомендации, второй пересмотр. Кардиоваскулярная терапия и профилактика. 2008; 7(6). Приложение 4.
11. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blokers, angiotensin-converting enzyme inhibitors, and statins after myocardial infarction. Eur Heart J 2006; 27: 1153-8.
12. Daly CA, Clements F, Lopez Sendoz JL, et al. The initial management of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005; 26: 1011-22.
13. Daly CA, Clements F, Lopez Sendoz JL, et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27: 1298-304.
14. Daly C, Tavazzi L, Fox K, on behalf of Euro Heart Survey of Angina Investigators. Inadequate control of heart rate in patients with stable angina: results from the European Heart Survey. Eur Heart J 2008; 29(Suppl): 204-5.
15. Vliegen HW, van der Wall EE, Niemeyer MG, et al. Long-term efficacy of diltiazem controlled release versus metoprolol in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991; 18 (Suppl. 9): S55-60.
16. Fox K, Ford I, Steg PG, et al. on behalf of the BEAUTIFUL investigators. Ivabradine fro patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; Published Online August 31, 2008.
17. Fox K, Ford I, Steg PG, et al. on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008. Published Online August 31, 2008.
Review
For citations:
Lopatin Yu.M. Will the BEAUTIFUL Study results change our views on heart rate control? Cardiovascular Therapy and Prevention. 2008;7(8):70-74. (In Russ.)
Views:
372
Email this article 
